Journal list menu
Author Guidelines
SECTIONS
1. AIMS AND SCOPE
2. SUBMISSION
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS
4. PREPARATION OF THE MANUSCRIPT
5. EDITORIAL POLICIES AND CONTENT CONSIDERATIONS
6. PUBLICATION PROCESS AFTER ACCEPTANCE
7. COPYRIGHT, LICENSING AND OPEN ACCESS
8. POST PUBLICATION
9. ONLINE ACCESS TO MANUSCRIPTS
10. EDITORIAL OFFICE CONTACT DETAILS
1. AIMS AND SCOPE
First published in 1982, Drug and Alcohol Review is Asia-Pacific’s leading multidisciplinary journal addressing issues related to alcohol and other drug related problems and connected matters. As the official journal of the Australasian Professional Society on Alcohol and other Drugs (APSAD), Drug and Alcohol Review is an international meeting ground for the views, expertise and experience of all those involved in studying matters relating to alcohol and other drugs. Contributors to the Journal examine and report on these matters from a wide range of clinical, epidemiological, psychological and social science perspectives. Drug and Alcohol Review particularly encourages the submission of papers which have a harm reduction perspective, or which are policy-relevant. However, the principal criterion for publication of papers is their scientific quality.
2. SUBMISSION
Authors should kindly note that submission implies that the content has not been published and is not being submitted for publication elsewhere, except as a brief abstract in the proceedings of a scientific meeting or symposium.
Once the submission materials have been prepared in accordance with the author guidelines, new submissions should be made via the Research Exchange submission portal: https://wiley.atyponrex.com/journal/DAR.
You may check the status of your submission at any time by logging on to submission.wiley.com and clicking the "My Submissions" button. For technical help with the submission system, please review our FAQs or contact [email protected].
For editorial enquiries, please contact [email protected].
To ensure fast peer review and publication, manuscripts that do not adhere to the following instructions will be returned to the corresponding author for revision before undergoing peer review. Please note that reviewers will remain anonymous but will be able to see the authors’ details. Reviewers are asked to advise of any conflicts of interest with authors.
Authorship
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics and scroll down for a description of authorship criteria. Further information is also available under ‘Author contribution statement’ in the Title Page section.
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS
Word, Table/Figure and Reference Limits
Our editorial approach is centred on accuracy and effective communication, and thus we encourage authors to take particular care in determining the minimum number of words, tables, figures and references necessary to report their study and ideas. Authors should bear in mind that material not essential to the paper but which may be necessary for replication can be included in supporting online information (see section (i) below). We encourage data and statistical syntax files that would aid independent replication to be included as supplementary material.
The word lengths provided as guidelines below are for the main text only, excluding the title page, abstract, acknowledgements, references and any tables or figures. We suggest a maximum of five tables and figures (combined) for original research papers and two for Brief Reports – see (g) Tables and Figures, below.
We understand that in some cases (e.g. reporting of mixed methods studies), articles may need to be longer or include more tables/figures than our guidelines stipulate, and we aim to be flexible to accommodate such needs. If authors think they have to significantly exceed these guidelines to report the findings effectively, they should explain why in the cover letter.
Manuscripts are published in the following sections.
Original Papers – reports of new research findings or conceptual analyses that make a significant contribution to knowledge (guideline of 3500 words). Papers analysing qualitative fieldwork or documentary materials (normally without tables) have a guideline of 5000 words (see under “Reporting Guidelines” below for further details). Ordinarily, original papers should aim to have no more than 40 references.
Commentaries and For Discussion – evidence-based opinion pieces involving areas of broad interest (guideline of 1500 words) and invited commentaries. Comments are pieces where the editors have decided to invite comments (guideline of 1000 words) from scholars on another paper.
Reviews: Drug and Alcohol Review accepts submissions of all types of reviews, provided they include: a clear description of how studies were identified and included; a synthesis of research findings; and implications of findings for research, clinical practice and/or policy. Registration of review protocols is strongly encouraged. Reporting guidelines for the selected review type should be followed and the completed checklist submitted with the manuscript. Reporting guidelines for most study types can be found at https://www.equator-network.org/. Authors may also wish to consult Sutton et al. to understand different types of reviews and their requirements. Additional guidance for specific types of reviews:
-
Systematic reviews of quantitative data with or without meta-analysis (guideline of 5000 words). Systematic reviews with a meta-analysis should be reported in line with the PRISMA statement. Systematic reviews of quantitative data without a meta-analysis should follow the SWiM reporting guideline in addition to PRISMA.
-
Rapid reviews (guideline of 2000 words). Rapid reviews should be reserved for emerging areas in the alcohol and other drugs field and related matters. To enable timely summaries of critical topics for clinicians, service managers, policy makers and/or researchers, components of the systematic review process may be simplified or omitted (e.g. limiting time frames, databases, bias assessments or other methodological aspects of a typical systematic review) to produce an information summary in a short period of time (Tricco et al. 2015). A rapid review article would typically be commissioned and follow normal peer review processes, although authors are welcome to contact the Editorial Office with a brief proposal for consideration.
-
Narrative reviews (guideline of 5000 words). Narrative reviews should summarise literature comprehensively but may not be explicitly systematic. They should include structured headings, with text on the purpose of the review; information sources consulted; how information was integrated, analysed and synthesised; key findings (and recommendations, if any); and limitations. For key findings and recommendations, a statement on the strength of the evidence, and how this was determined, should be included.
-
Other types of reviews (including but not limited to qualitative evidence syntheses, scoping reviews, realist syntheses and mixed methods reviews) are welcome and have a guideline of 5000 words. Authors should refer to methodological guidance and/or reporting guidelines for their selected review type as appropriate.
Brief Reports – preliminary findings or studies with substantive findings that require fewer words and tables/figures to give a complete account of the research (guideline of 1500 words). Ordinarily, Brief Reports should aim to have no more than 20 references.
Case Reports and Case Series – Drug and Alcohol Review will only publish a limited number of case reports and case series (guideline of 1500 words), limited to high quality descriptions of cases that make a unique contribution to the literature through description of an unusual presentation, support or contest a hypothesis, or offer new insights into a condition or treatment. The submission should provide new information on diagnosis or clinical care that can lead to practice change care relating to drug and alcohol use. See under “Reporting Guidelines” below for further details.
Obituaries –Drug and Alcohol Review will publish obituaries related to the life and works of prominent researchers and others who have substantially contributed to the alcohol and other drugs field (approximately 350-500 words). Typically commissioned, obituaries are brief overviews of the deceased person’s life and major contributions. Along with an appreciation of their work and personal traits, please include the person’s birth and death years, place of birth, names and cities of the major institutions where the person worked, positions of importance held, and other interests outside work in the field. Approaches to publish obituaries should be made to the Editorial Office.
Editorials – are usually commissioned but unsolicited material may be considered. Please approach the Editorial Office before submitting this material.
Letters to the Editor – are welcomed and will be summarily reviewed (guideline of 1000 words).
Critiques – reviews of books or grey literature are welcomed, but please approach the Editorial Office before submitting a review (guideline of 800 words).
Special Issues and Special Sections on topics of interest are also regularly published. A proposal must be approved by the Editorial Board, which should initially be sent to the Editorial Office. Papers for a Special Issue or Section should be submitted as the appropriate article type (e.g. Original Paper, Review). Please include a note in the cover letter to indicate which Special Issue or Section the paper is intended for.
4. PREPARATION OF THE MANUSCRIPT
Artificial Intelligence Generated Content
In accordance with COPE’s position statement on AI tools, Artificial Intelligence Generated Content (AIGC) tools – such as ChatGPT and others based on large language models (LLM) – cannot fulfill the role of, nor be listed as, an author of an article. If an author has used this kind of tool to develop any portion of a manuscript, its use must be described, transparently and in detail, in the Methods or Acknowledgements section. The author is fully responsible for the accuracy of any information provided by the tool and for correctly referencing any supporting work on which that information depends. Tools that are used to improve spelling, grammar and general editing are not included in the scope of these guidelines.
Further information is available at https://authorservices.wiley.com/ethics-guidelines/index.html#3
Authors are asked to disclose if and how AI technology has been used, consistent with the guidelines from ISAJE https://www.isaje.net/ai-statement.html
Manuscript Style
We encourage high quality writing and refer our authors to the many writing guides available online, such as Kipling’s Guide to Writing a Scientific Paper. Manuscripts should follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors’ revised Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication. We also encourage the use of non-stigmatising language as outlined by the International Society of Addiction Journal Editors (see: http://www.isaje.net/addiction-terminology.html). Expression should generally refer to alcohol and other drugs to reflect the status of alcohol as a drug.
- Spelling: Drug and Alcohol Review uses English (UK) spelling.
- Units: All measurements must be given in International System (SI) or SI-derived units with traditional units in parentheses; exceptions are blood pressure which should be expressed in mm Hg and haemoglobin concentration (g/dL). Blood alcohol level or other alcohol levels must be expressed in percentages (e.g. BAL 0.05%, which means 0.05 g (50 mg) of alcohol in every 100 ml of blood).
- Abbreviations: The journal strictly limits the use of abbreviations to lengthy terms that are used at least three times, with the exception of abbreviations of certain standard units of measurement and statistical measures such as SD. All abbreviations should be written in full on their first use, followed by the abbreviation in parentheses.
- Trade names: Drugs should be given their approved, not proprietary, names and the source of any new or experimental preparation should be given.
Parts of the Manuscript
A cover letter should be included in the ‘Cover Letter’ section of the submission system. The text may be entered directly into the field or uploaded as a file.
Please submit a main document file using Microsoft Word that includes all parts of the text in the sequence indicated below, including tables and figures.
Manuscripts should be presented in the following order:
(a) Title page
(b) Abstract and key words
(c) Key point summary
(d) Text
(e) Acknowledgements
(f) References
(g) Tables and Figures (can be included where mentioned in the main document, at the end of the main document or uploaded separately)
(h) Appendices (to be part of the main document)
(i) Supporting online information
(a) Title page
The title page should contain:
1. The title of the paper – the title should be concise and informative, with no abbreviations.
2. A short running title of no more than 40 characters, including spaces.
3. Each author’s full name and affiliation (department, institution, city and country).
4. The full postal address, email address and telephone number (optional) of the corresponding author.
5. Conflicts of interest statement.
The second page should include a structured abstract of no more than 250 words, using the following headings:
- For Original Papers and Brief Reports – Introduction, Methods, Results, Discussion and Conclusions.
- For Reviews– Issues, Approach, Key Findings, Implications, Conclusion.
- For Case Reports and Case Series – Introduction, Case Presentation, Discussion and Conclusions.
- Abstracts are encouraged but not required for Commentaries, Comments and Editorials, and can be unstructured.
For the purposes of indexing, a maximum of five key words should be supplied below the abstract and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list.
(c) Key point summary
This should include three to five dot points which outline the key findings and significance of the paper. These are not mandatory at first submission but will be requested before a paper is accepted. Key points are not required for editorials, commentaries, comments or letters to the editor.
(d) Text
The text of Original Papers should conform to the conventional structure for scientific communications – introduction, methods, results, discussion and conclusions. We encourage a succinct introduction (guideline of 800 words). The format of Reviews, Commentaries and Comments is likely to differ from this and authors should consult previous issues of the journal for guidance. Brief Reports should generally conform to the format of original papers. All results should be justified by describing the methods employed (in the methods section), including details of the data and analytical approach, and the results of any statistical analyses.
Any reimbursement of participants should be declared in the Methods section.
We suggest authors follow guidelines for the discussion section of their paper, as reported in the British Medical Journal:
- Statement of principal findings;
- Strengths and weaknesses of the study;
- Strengths and weaknesses in relation to other studies, particularly discussing any differences in results;
- Meaning of the study: possible mechanisms and implications for clinicians or policymakers;
- Unanswered questions and future research.
Further information on the requirements for randomised controlled trials; reviews; case-controlled, cohort, cross-sectional studies; case reports and case series; and qualitative papers can be found under Reporting Guidelines.
Endnotes will be allowed where information cannot be explained in the text, but should not be used for references or side-comments. There is a guideline of five endnotes.
Statistical information should be reported consistently throughout the manuscript.
- We prefer 95% confidence intervals and where they are not appropriate, P-values with three decimal places, with P<0.001 where the P-value is smaller.
- For decimal fractions less than 1.00, use a zero in the whole-number position (e.g. 0.01).
- Confidence intervals should be expressed using commas rather than dashes or “to” (e.g. 1.23, 1.39).
- Meaningful regression terms should be used (e.g. odds ratios rather than beta coefficients in logistic regression). With continuous outcomes, coefficients must be specified in relation to the unit of measurement.
- Round percentages to whole numbers where the base for the percentage is less than 100. Percentages otherwise should be reported to one decimal place.
(e) Acknowledgements
Contributions of colleagues or institutions can be acknowledged but personal thanks or appreciation of anonymous reviewers is not appropriate. Trial registration number and name of the public trial registry should be listed here for a study with such registration.
(f) References
For first submission, any style of referencing can be used, as long as in-text references and a reference list are included. However, please note that published papers are required to use the Vancouver system of referencing, and if the paper is accepted authors will be asked to convert references before it is prepared for publication.
References should be numbered consecutively in the order in which they are first mentioned in the text. If references are cited in tables or figures, number according to the placement in the text of the first identification of the table or figure. Avoid the use of abstracts as references. References to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2011, unpublished data). Manuscripts accepted in final form but not yet published may be referenced; the journal should be named and the phrase ‘(in press)’ should follow. For papers which have been published online but not yet assigned a volume or page numbers, include the phrase ‘[Epub ahead of print]’ and the paper’s Digital Object Identifier (DOI). All citations mentioned in the text, tables or figures must be listed in the reference list. Conversely, the reference list may not include works not cited.
Journal titles should be abbreviated as they would appear in the US National Library of Medicine catalogue. Indicate references in the text using Arabic numbers inside square brackets (e.g. [1] or [2-7] or [4, 5]). In the reference list, cite the names of all authors – ‘et al.’ can be used after the sixth author’s name if there are seven or more authors.
We recommend the use of software such as Endnote for reference management and formatting.
References should be formatted as follows:
Journal articles
[1] Rose G. International trends in cardiovascular disease: implications for prevention and treatment. Aust NZJ Med 2005;14:375-80.
[2] Reeves S, Bertrand J, Uchida H, Yoshida K, Otani Y, Ozer M, et al. Towards safer risperidone prescribing in Alzheimer’s disease. Br J Psychiatry. 2021;218:268-75.
Book
[3] Henderson S, Byrne DG, Duncan-Jones P. Neurosis and the social environment, 3rd edn. Sydney: Academic Press, 1981.
Book Chapter
[4] Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In: Sodeman WA Jr, Sodeman WA, eds. Pathologic physiology: mechanisms of disease. Philadelphia: WB Saunders, 1999:457-72.
Website
[5] Oxford Centre for Evidence-based Medicine. Levels of Evidence (March 2009). Available at: http://www.cebm.net/index.aspx?o=1025 (accessed November 2011).
(g) Tables and Figures
There should be a maximum of five tables and figures combined for original research papers and two for Brief Reports. Requests to exceed these limits will be considered on a case-by-case basis.
Tables
Tables should be self-contained and complement, not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Explanatory matter, including definition of abbreviations, should be placed in footnotes to a table. Tables can be added in the main document where mentioned, included at the end of the main document or uploaded as separate files. The legend should be below the table, and should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses. If data come from another published or unpublished paper, the original source should be cited.
Figures
All illustrations (line drawings and photographs) are classified as figures. Figures should be numbered using Arabic numerals, and cited in consecutive order in the text. Effective 1 January 2024, the journal is an online only journal. Color figures will be published free of charge. Printed copies of the journal may be purchased through a print-on-demand service. Figures can be added in the main document where mentioned, included at the end of the main document or uploaded as separate files, with the figure number incorporated in the file name.
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes and resolutions are accepted.
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.
Figure legends
Figure legends should accompany figures when included in the manuscript file or be typed on a separate page when figures are uploaded as separate files. In the published version, the legend will appear below the figure. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement, either as a box incorporated in the figure or in the legend.
(h) Appendices
Appendices should be kept short and confined to information needed to understand material in the main paper. They should be included at the end of the main document and will appear in the print and online version of the article.
(i) Supporting online information: Supporting information is not essential to the article but contains information that would be necessary to replicate the study, or provides greater depth and background and may include tables, figures, videos, datasets, etc. This material can be submitted with your manuscript and will appear online, without editing or typesetting.
Supporting information should be submitted as a separate file/s, with sections numbered in Roman numerals, with the prefix ‘S’ (e.g. Table S1, Figure S1) and be referred to in the text. If written by a person other than the author/s of the main text, their name/s should be included below the title.
Guidelines on how to prepare this material and which formats and files sizes are acceptable can be found at: http://authorservices.wiley.com/bauthor/suppmat.asp
Reproduction of Copyright Material
If excerpts from copyrighted works owned by third parties are included (e.g. figures), credit must be shown in the contribution. It is the corresponding author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ.
The corresponding author is responsible for obtaining written permission to reproduce the material “in print and other media” from the publisher of the original source, and for supplying Wiley with that permission upon submission
Wiley Author Resources
Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization. The Wiley ‘Author Services’ website also includes useful information covering such topics as copyright matters, ethics and electronic artwork guidelines.
Editing, Translation and Formatting Support: Wiley Editing Services can greatly improve the chances of a manuscript being accepted. Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Other services include manuscript formatting and figure preparation. Visit Wiley Editing Services to learn about the options. All services are paid for and arranged by the author. Please note using Wiley Editing Services does not guarantee that your paper will be accepted by this journal.
Optimising Your Article for Search Engines: Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. Wiley have compiled guidelines to enable you to maximise the web-friendliness of the most public part of your article.
5. EDITORIAL POLICIES AND CONTENT CONSIDERATIONS
Papers are accepted on the basis of the quality and originality of the research and its significance to our readership. All manuscripts receive full consideration, and those deemed appropriate for consideration for publication are normally peer reviewed by at least two reviewers and a Managing Editor from the Editorial Board. Final acceptance or rejection rests with the Editorial Board.
Reviewers will remain anonymous but can view the authors’ details. Reviewers are asked to keep all details of the review confidential and to advise if there are any conflicts of interest.
Drug and Alcohol Review follows Wiley’s policy on confidentiality of the review process.
Publication Ethics
International Society of Addiction Journal Editors (ISAJE) Ethical Practice Guidelines provide guidance to authors ‘regarding ethical and procedural issues that affect the integrity of scientific publishing’. We ask that authors read and observe these guidelines, especially in regard to study design and ethical approval, consent, authorship, conflict of interests, plagiarism and redundant publication.
An ethics statement should be included in the Methods section if applicable.
Principles for Publication of Research Involving Human Subjects
Manuscripts which report on data collected from human subjects should contain a statement to the effect that all studies have been reviewed by the appropriate ethics committee or Institutional Review Board and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the Declaration of Helsinki (as revised in Brazil 2013). For studies where this applies, it should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under the study should be omitted. In cases where approval has not been sought or would not normally be required, please indicate the reasons for non-approval in the covering letter.
Research conducted with Aboriginal and Torres Strait Islander, Māori or other First Nations Peoples
It is important that research related to Aboriginal and Torres Strait Islander, Māori and other First Nations Peoples is conducted so as to be safe, respectful, responsible, of high quality and is of benefit. It is expected that research that is specific to or has a focus on First Nations Peoples will have approval from an appropriate First Nations Human Research Ethics Committee or a First Nations Research Institutional Review Board. Where there is no such review process, researchers need to state the nature and depth of involvement by First Nations Peoples in developing, undertaking and reporting on the research project and this should be described in the methods. It is highly desirable for any papers that have a First Nations focus that member/s of the authorship team are First Nations People of the same background as the participants.
Registration
All randomised controlled trials (RCT) involving clinical populations must be registered with a public trials registry such as the Australian and New Zealand Clinical Trials Register. The trial registration number and name of the registry will need to be cited in the acknowledgement section of the paper. If the commencement of the trial precedes the registration date, please explain why in the cover letter. We encourage registration for non-RCT studies, including cohort studies, policy evaluations and other observational epidemiological studies.
Reporting Guidelines
- RCTs: The CONSORT Statement provides evidence-based recommendations for reporting RCTs. All RCTs must follow the CONSORT Guidelines including the checklist and flow diagram.
- Reviews: The PRISMA Statement encourages transparent reporting of meta-analyses and systematic reviews. Where appropriate, the PRISMA checklist and flow diagram should be included. To view the PRISMA Statement and Guidelines click here. For systematic reviews without meta-analysis, the SWIM Guidelines should also be included.
- Case-Controlled, Cohort, Cross-Sectional Studies: Refer to the STROBE Statement and checklist for reporting.
- Case Reports and Case Series: Submissions should adhere to guidance on the publication of case reports, including providing evidence of patient consent using a consent form (please include a statement that the patient has provided consent and have proof available if requested), or evidence of ethics committee approval for publication of the case report or case series without the patient’s consent.
- Qualitative papers: The following criteria will be used to review papers which are based on qualitative material – observations, recorded conversations or open-ended responses or documentary material – including such work as ethnographic, historical and policy studies. Please note that there is a guideline of up to 5000 words and tables and figures are not typically included. If authors think they have to exceed these limits to report the findings effectively, they should explain why in the cover letter.
Defamatory Statements
Authors should refrain from making defamatory statements about specific individuals or organisations, and familiarise themselves with defamation laws in Australia and their own jurisdictions. However, the journal is committed to publishing material which raises issues and makes comments about the behaviour of sectors such as the alcohol or pharmaceutical industry, and we will analyse and critique research and claims made by vested interests.
The views, information and opinions expressed in articles included in this journal are solely the author’s own views and do not necessarily represent the views of APSAD or its members, and APSAD does not assume any responsibility or liability for the information, views or opinions. APSAD reserves the right to refuse work submitted to the journal where APSAD considers the work contains statements or imputations likely to be ruled to be defamatory.
Data Sharing and Data Accessibility
The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement at the end of their paper, including a link to the repository they have used, in order that this statement can be published alongside their paper.
6. PUBLICATION PROCESS AFTER ACCEPTANCE
Accepted papers will be passed to Wiley’s production team for publication. The author identified as the formal corresponding author for the paper will receive an email prompting them to login into Wiley’s Author Services, where via the Wiley Author Licensing Service (WALS) they will be asked to complete an electronic license agreement on behalf of all authors on the paper. More details on the copyright and licencing options for the journal appear below.
Wiley’s Author Services
Author Services enables authors to track their article through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production. The corresponding author will receive a unique link that enables them to register and have their article automatically added to the system. Please ensure that a correct email address is provided when submitting the manuscript. Visit https://authorservices.wiley.com/home.html for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
Proofing
Once the paper has been typeset, the corresponding author will receive an email containing instructions on how to provide proof corrections. It is therefore essential that a working email address be providing for the corresponding author. Proofs should be corrected carefully; the responsibility for detecting errors lies with the author.
Early View
The journal offers rapid speed to publication via Wiley’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. Early View articles are given a DOI, which allows the article to be cited and tracked before allocation to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.
Author Marketing Toolkit
The Wiley Author Marketing Toolkit, available through Author Services, provides authors with support on how to use social media, publicity, conferences, multimedia, email and the web to promote their article.
7. COPYRIGHT, LICENSING AND OPEN ACCESS
Authors may choose to publish under the terms of the journal’s standard copyright transfer agreement at no charge, or pay to have the paper published under open access terms made available via Wiley Open Access.
Standard Copyright Transfer Agreement: FAQs about the terms and conditions of the standard copyright transfer agreement in place for the journal, including standard terms regarding archiving of the accepted version of the paper, are available at http://www.wileyauthors.com/licensingFAQ.
Note that in signing the journal’s licence agreement authors agree that consent to reproduce figures from another source has been obtained.
General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under Open Access, please click here. (Note that certain funders mandate a particular type of Creative Commons license be used; to check this please click here.)
Self-Archiving Definitions and Policies: Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.
Wiley’s Open Access Option: Open Access is available to authors of articles who wish to make their article freely available to all on Wiley Online Library under a Creative Commons license. Authors who choose to publish using Open Access will be charged a fee. A list of Article Publication Charges for Wiley journals is available here. With Open Access, the author, the author’s funding agency or the author’s institution pays a fee to ensure that the article is made open access. Authors of Open Access articles are permitted to post the final, published PDF of their article on their personal website, and in an institutional repository or other free public server immediately after publication. All Open Access articles are treated in the same way as any other article. They go through the journal’s standard peer-review process and will be accepted or rejected based on their own merit.
Authors affiliated with an institution that has an Open Access agreement may be able to publish primary research and review articles Open Access at no charge to the author. More information is available here: https://authorservices.wiley.com/author-resources/Journal-Authors/open-access/affiliation-policies-payments/index.html
Open Access licenses: Authors choosing Open Access retain copyright in their article and have a choice of publishing under the following Creative Commons License terms: Creative Commons Attribution License (CC BY); Creative Commons Attribution Non-Commercial License (CC BY NC); Creative Commons Attribution Non-Commercial-NoDerivs License (CC BY NC ND). To preview the terms and conditions of these open access agreements please visit http://www.wileyauthors.com/licensingFAQ.
Funder Open Access and Self-Archiving Compliance: Please visit Author Services for more information on Wiley’s compliance with specific Funder Open Access and Self Archiving Policies, and for more detailed information specifically about self-archiving definitions and policies.
Access and Sharing
When the article is published online:
- The corresponding author receives an email alert a few days before the paper is due to be published on Early View and one when the paper has been published.
- The link to the published article can be shared through social media.
- The author will have free access to the paper (after accepting the Terms & Conditions of use).
- The corresponding author and co-authors can nominate up to 10 colleagues to receive a publication alert and free online access to the article.
Print copies of the article can be ordered (instructions are sent at proofing stage or email [email protected]).
To find out how to best promote an article, click here.
Measuring the Impact of an Article
Wiley also helps authors measure the impact of their research through a specialist partnership with Altmetric.
9. ONLINE ACCESS TO MANUSCRIPTS
Papers published in Drug and Alcohol Review will be permanently available by subscription or purchase on the Wiley Online Library website. Authors can also make their paper freely available on the Drug and Alcohol Review website through open access (see information on Open Access above). Authors may post an electronic version of their article on their own personal website, their employer’s website/repository or on free public servers in their subject area. This electronic version of the article may be of the final accepted version but not as typeset and formatted by the publisher, and must include a link to the published version of the article, together with the following text: “The definitive version is available at www.onlinelibrary.wiley.com”. For papers supported by an Australian funding agency which requires open access publication, the paper will be made available by open access on the Wiley site within 12 months of publication. For US NIH funded research and other funding bodies requiring Open Access please refer to Wiley’s Open Access policy:
10. EDITORIAL OFFICE CONTACT DETAILS
Editorial Officer
Drug and Alcohol Review
PO Box R1014, Royal Exchange
NSW 1225
AUSTRALIA
Tel.: +61(0)2 9252 2281
Email: [email protected]